Keyword: Daiichi Sankyo

AstraZeneca manufacturing employee

44. Enhertu

AstraZeneca and Daiichi Sankyo hoped their antibody-drug conjugate could help a tough-to-treat group of breast cancer patients—and the FDA agreed to give it a shot in late December despite a shaky safety profile.
Turalio

18. Turalio

While Daiichi Sankyo previously worked on the BRAF inhibitor Zelboraf with Genentech, Turalio represents its first solo cancer drug—and one of seven that Daiichi Sankyo hopes to obtain approvals for by 2025.